Veradermics is trading 4.16% down at $117.31 on October 13, 2026, with biotech-sector weakness potentially contributing. - No new company-specific announcement or event explaining the decline was identified; coverage instead points to investor focus on future Phase 3 readouts. - The supplied market context shows XBI down 2.01% during the session, while broader major indexes were nearly flat. - The evidence supports sector pressure rather than a company-specific catalyst, but does not establish a definitive cause.